Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold

Código QR

Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefan Toggweiler, Matthias Bossard, Florim Cuculi, Federico Moccetti, Mathias Wolfrum, Richard Kobza, Adrian Attinger-Toller, Mehdi Madanchi, Giacomo Maria Cioffi, Thomas Seiler, Luca Vercelli, Philipp Burkart
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/33b409893709413c9d06b7331e6556d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction
por: Piotr Desperak, et al.
Publicado: (2020)

Everolimus-eluting coronary stents
por: Alejandro Saez, et al.
Publicado: (2010)

Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
por: Beytullah Cakal, et al.
Publicado: (2020)

Everolimus-eluting stents: update on current clinical studies
por: Allocco DJ, et al.
Publicado: (2011)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas VF, et al.
Publicado: (2015)

Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
por: Josep Gomez‐Lara, et al.
Publicado: (2021)

Absorb BRS for in-stent restenosis: the final bow before (scaffold) collapse?
por: Stéphane Cook, et al.
Publicado: (2021)

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
por: Bennett J, et al.
Publicado: (2013)

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
por: Sanchez OD, et al.
Publicado: (2014)

Computational and experimental mechanical performance of a new everolimus-eluting stent purpose-built for left main interventions
por: Saurabhi Samant, et al.
Publicado: (2021)

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
por: Yong Zhu, et al.
Publicado: (2021)

Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation
por: In-Ho Bae, et al.
Publicado: (2018)

Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model
por: Suguru Migita, et al.
Publicado: (2021)

Restenosis After Tack Implantation is Associated with Less Complex Patterns of Restenosis Compared to Stent Implantation
por: Raghu Kolluri, et al.
Publicado: (2020)

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes
por: Grzegorz K. Jakubiak, et al.
Publicado: (2021)

Long-term outcomes of Absorb bioresorbable vascular scaffold using predilation, sizing, and postdilation protocol in a real-world patient population
por: Sinem Çakal, et al.
Publicado: (2021)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Huilin Hu, et al.
Publicado: (2021)

Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases
por: Kun Zhang, et al.
Publicado: (2021)

Early scaffold strut coverage in ultra-high molecular weight amorphous PLLA sirolimus-eluting bioresorbable scaffolds: impact of strut thickness assessed in normal porcine coronary arteries
por: Paweł Gąsior, et al.
Publicado: (2020)

Bioresorbable scaffolds in the treatment of coronary artery disease
por: Zhang Y, et al.
Publicado: (2013)

Corrigendum to “A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway” [Bioact. Mater. 6 2 (February 2021) 375–385]
por: Yinping Zhao, et al.
Publicado: (2022)

Biodegradable Cable-Tie Rapamycin-eluting Stents
por: Cheng-Hung Lee, et al.
Publicado: (2017)

Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis
por: Melanie Haidegger, et al.
Publicado: (2021)

A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine
por: Ikushima I, et al.
Publicado: (2011)

Bioresorbable vascular scaffolds technology: current use and future developments
por: Giacchi G, et al.
Publicado: (2016)

New drug-eluting stents: technological refinement continues
por: Javier Suárez de Lezo, et al.
Publicado: (2021)

A case of in stent restenosis (ISR) treated with drug-coated balloons (DCB) in a young diabetic with multiple stents
por: Tutan Das, et al.
Publicado: (2021)

Clonal diversity of the B cell receptor repertoire in patients with coronary in-stent restenosis and type 2 diabetes
por: Weng Ruiqiang, et al.
Publicado: (2021)

IN STENT RESTENOSIS (ISR) IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR CORONARY ARTERY DISEASE (CAD)
por: Waseem Raja, et al.
Publicado: (2020)

Iterative reconstruction improves detection of in-stent restenosis by high-pitch dual-source coronary CT angiography
por: Junjie Yang, et al.
Publicado: (2017)

High coronary calcium score and post-procedural CK-MB are noninvasive predictors of coronary stent restenosis
por: Lee JB, et al.
Publicado: (2017)

Promoting vascular healing using nanofibrous ticagrelor-eluting stents
por: Lee CH, et al.
Publicado: (2018)

Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina M, et al.
Publicado: (2011)

Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies.
por: Xinlin Zhang, et al.
Publicado: (2014)

Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency
por: Rory Marples, MBBS, et al.
Publicado: (2022)

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
por: Kim DH, et al.
Publicado: (2013)

Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
por: Brendan Doyle, et al.
Publicado: (2009)

Saphenous Vein Graft Aneurysm after Drug-Eluting Stent Implantation: Treatment by Covered Stent
por: Kyriacos Papadopoulos, et al.
Publicado: (2021)

Advances in drug eluting stents &ndash; focus on the Endeavor&reg; zotarolimus stent
por: Jonathan Bridges, et al.
Publicado: (2008)

Optical computed tomography (OCT) guided follow up of primary PCI patients for predicting factors for restenosis and late stent malapposition
por: Swati Sharma, et al.
Publicado: (2021)